Actavis, Noven Reach Deal Over Generic ADHD Patch Plans

Law360, Washington (March 20, 2014, 4:16 PM EDT) -- Actavis PLC has reached a licensing deal with Noven Pharmaceuticals Inc. to make a generic version of Noven's attention deficit hyperactivity disorder treatment Daytrana, it announced Wednesday, ending patent litigation over the drug in New Jersey federal court.

Under the terms of the deal, Miami-based Noven — a unit of Japanese drugmaker Hisamitsu Pharmaceutical Co. Inc. — will grant its Irish-American rival a nonexclusive, royalty-bearing license to market generic methylphenidate transdermal patches beginning in September 2015, or earlier under certain unspecified circumstances. Other details of the...
To view the full article, register now.